High-affinity Antibodies to the 1,4-dihydropyridine Ca2+-channel Blockers

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1986 May 1

PMID 3010317

Citations 1

Authors

K P Campbell

A Sharp

M Strom

S D Kahl

Affiliations

Soon will be listed here.

Abstract

Antibodies with high affinity and specificity for the 1,4-dihydropyridine Ca2+-channel blockers have been produced in rabbits by immunization with dihydropyridine-protein conjugates. Anti-dihydropyridine antibodies were found to specifically bind [3H]nitrendipine, [3H]-nimodipine, [3H]nisoldipine, and [3H]PN 200-110 (all 1,4-dihydropyridine Ca2+-channel blockers) with high affinity, while [3H]verapamil, [3H]diltiazem, and [3H]trifluoperazine were not recognized. The average dissociation constant of the [3H]nitrendipine-antibody complex was 0.06 (+/- 0.02) X 10(-9) M for an antiserum studied in detail and ranged from 0.01 to 0.24 X 10(-9) M for all antisera. Inhibition of [3H]nitrendipine binding was specific for the 1,4-dihydropyridine Ca2+-channel modifiers and the concentrations required for half-maximal inhibition ranged between 0.25 and 0.90 nM. Structurally unrelated Ca2+-channel blockers, calmodulin antagonists, inactive metabolites of nitrendipine, and UV-inactivated nisoldipine did not modify [3H]nitrendipine binding to the anti-dihydropyridine antibodies. Dihydropyridines without a bulky substituent in the 4-position of the heterocycle were able to displace [3H]nitrendipine binding, but the concentrations required for half-maximal inhibition were greater than 800 nM. In summary, anti-dihydropyridine antibodies have been shown to have high affinity and specificity for the 1,4-dihydropyridine Ca2+-channel blockers and to exhibit dihydropyridine binding properties similar to the membrane receptor for the 1,4-dihydropyridine Ca2+-channel blockers.

Citing Articles

Dystrophin Dp71: the smallest but multifunctional product of the Duchenne muscular dystrophy gene.

Tadayoni R, Rendon A, Soria-Jasso L, Cisneros B Mol Neurobiol. 2011; 45(1):43-60.

PMID: 22105192 DOI: 10.1007/s12035-011-8218-9.

References

Tsien R . Calcium channels in excitable cell membranes. Annu Rev Physiol. 1983; 45:341-58. DOI: 10.1146/annurev.ph.45.030183.002013. View

Bolger G, Gengo P, Klockowski R, Luchowski E, Siegel H, Janis R . Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle. J Pharmacol Exp Ther. 1983; 225(2):291-309. View

Muller R . Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay. Methods Enzymol. 1983; 92:589-601. DOI: 10.1016/0076-6879(83)92046-3. View

Schramm M, Thomas G, Towart R, Franckowiak G . Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature. 1983; 303(5917):535-7. DOI: 10.1038/303535a0. View

Venter J, Fraser C, Schaber J, Jung C, Bolger G, Triggle D . Molecular properties of the slow inward calcium channel. Molecular weight determinations by radiation inactivation and covalent affinity labeling. J Biol Chem. 1983; 258(15):9344-8. View

Janis R, Krol G, Noe A, Pan M . Radioreceptor and high-performance liquid chromatographic assays for the calcium channel antagonist nitrendipine in serum. J Clin Pharmacol. 1983; 23(7):266-73. DOI: 10.1002/j.1552-4604.1983.tb02734.x. View

Glossmann H, Ferry D . Solubilization and partial purification of putative calcium channels labelled with [3H]-nimodipine. Naunyn Schmiedebergs Arch Pharmacol. 1983; 323(4):279-91. DOI: 10.1007/BF00512465. View

Janis R, SCRIABINE A . Sites of action of Ca2+ channel inhibitors. Biochem Pharmacol. 1983; 32(23):3499-507. DOI: 10.1016/0006-2952(83)90295-2. View

Ferry D, Rombush M, Goll A, Glossmann H . Photoaffinity labelling of Ca2+ channels with [3H]azidopine. FEBS Lett. 1984; 169(1):112-8. DOI: 10.1016/0014-5793(84)80299-9. View

10.

Campbell K, Lipshutz G, Denney G . Direct photoaffinity labeling of the high affinity nitrendipine-binding site in subcellular membrane fractions isolated from canine myocardium. J Biol Chem. 1984; 259(9):5384-7. View

11.

Curtis B, Catterall W . Purification of the calcium antagonist receptor of the voltage-sensitive calcium channel from skeletal muscle transverse tubules. Biochemistry. 1984; 23(10):2113-8. DOI: 10.1021/bi00305a001. View

12.

Venter J, Berzofsky J, Lindstrom J, Jacobs S, Fraser C, Kohn L . Monoclonal and anti-idiotypic antibodies as probes for receptor structure and function. Fed Proc. 1984; 43(10):2532-9. View

13.

Costa M, Catterall W . Cyclic AMP-dependent phosphorylation of the alpha subunit of the sodium channel in synaptic nerve ending particles. J Biol Chem. 1984; 259(13):8210-8. View

14.

Borsotto M, Barhanin J, Norman R, Lazdunski M . Purification of the dihydropyridine receptor of the voltage-dependent Ca2+ channel from skeletal muscle transverse tubules using (+) [3H]PN 200-110. Biochem Biophys Res Commun. 1984; 122(3):1357-66. DOI: 10.1016/0006-291x(84)91241-5. View

15.

Smith T, Butler Jr V, Haber E . Characterization of antibodies of high affinity and specificity for the digitalis glycoside digoxin. Biochemistry. 1970; 9(2):331-7. DOI: 10.1021/bi00804a020. View

16.

SCHLOSSMANN K . [Fluorometric determination of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester and its main metabolite]. Arzneimittelforschung. 1972; 22(1):60-2. View

17.

Smith T . Ouabain-specific antibodies: immunochemical properties and reversal of Na + , K + -activated adenosine triphosphatase inhibition. J Clin Invest. 1972; 51(6):1583-93. PMC: 292297. DOI: 10.1172/JCI106956. View

18.

LOEV B, Goodman M, Snader M, Tedeschi R, MACKO E . "Hantzsch-type" dihydropyridine hypotensive agents. 3. J Med Chem. 1974; 17(9):956-65. DOI: 10.1021/jm00255a010. View

19.

Hoebeke J, Vauquelin G, Strosberg A . The production and characterization of antibodies against beta-adrenergic antagonists. Biochem Pharmacol. 1978; 27(11):1527-32. DOI: 10.1016/0006-2952(78)90480-x. View

20.

Caron M, Srinivasan Y, Snyderman R, Lefkowitz R . Antibodies raised against purified beta-adrenergic receptors specifically bind beta-adrenergic ligands. Proc Natl Acad Sci U S A. 1979; 76(5):2263-7. PMC: 383579. DOI: 10.1073/pnas.76.5.2263. View